UEG Week 2022

Personalized therapy - de-escalation strategies

The benefit of early intervention in CD

Treat-to-target with ustekinumab - why didn't it work?

What is new in anti-TNFα therapy?

Is IL-23 the super target?

Treat-to-target still alive?

What is the best dose of adalimumab in CD?

No matter what you use - treat early!

Postoperative monitoring matters!

Thinking out of the box - co-medication of the elderly

TYK2 Deucravacitinib in ulcerative colitis

Combination therapy: week 38 efficacy and safety data from the VEGA study

Treat-to-target strategy is superior to conventional step-care in active patients to gain remission

Treating the patient as a whole

Pharmacokinetics of ustekinumab in the STARDUST trial

VEGA - the story continues

Anti-IL-23 monoclonal antibodies: is it better to target IL-23 only than IL-23 and IL-12?

Small molecules in crohn's disease

Longterm potential benefit of a combIo therapy

Once more a shocking message: be aware of steroids!

Explosion of new drugs

Enhanced treatment algorithm for the management of CD

Oral anti-integrin therapy in IBD - new data, new chances?

T reg - a new therapeutic target in IBD?

You can still treat severe biofailure in CD

VEGA - l'histoire continue

Small molecules nel morbo di crohn

Thinking out of the box - Einfluss der Begleitmedikation bei älteren Patienten

Anticorps anti-IL-23: est-il préferabble de cibler l'IL-23 seule plutôt que l'IL-12 et l'IL-23?

Terapia di combinazione: efficacia e sicurezza a 38 settimane nello studio VEGA

TYK2 Deucravacitinib bei Colitis ulcerosa

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά νόσο του Crohn

Una strategia “Treat-to-target” è superiore rispetto and un approccio convenzionale nel raggiungimento della remissione in pazienti con malattia attiva

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα κορτικοστεροιδή!

Explosión de nuevos fármacos

Doustna terapia antyintegrynowa - nowe dane, nowe nadzieje?

Les résultats à long terme d'une combIothérapie

T reg - nowy cel terapeutyczny w IBD?

Treating the patient as a whole

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

Was tun nach der Operation?

S1P receptor modulators

Update on IL-23 inhibition in UC

1st JAK inhibitor in CD - a game changer?

Update on JAK inhibition in UC

Upadacitinib maintenance therapy - final results from U-ACHIEVE

Persistance on therapy and real-world clinical effectiveness of Tofacitinib in ulcerative colitis: data from the ENEIDA registry

Final efficacy and safety results from Upadacitinib 52 weeks maintenance trial in UC patients

Estrasimod in moderate to severe active UC

Histological response and remission induced by mirikizumab

The era of small molecules

Upadacitinib - induction therapy in CD

JAK-inhibition

Ozanimod works in young and old UC patient

VEGA & LUCENT studies

Risankizumab in refractory CD patients

The 1st JAKi in CD

Selective IL-23 blockade

VEGA & LUCENT studi clinici

Persistenza in terapia ed efficaci clinica di Tofacitinib in colite ulcerosa: dati dal registro ENEIDA

Risankizumab dans la maladie de Crohn réfractaire

Upadacitinib - Induktionsdaten bei CD

Risultati finali di efficacia e sicurezza a 52 settimane di Upadacitinib in colite ulcerosa

The area of small molecules

JAK-Inhibition

Selective IL-23 Blockade

Treating the elderly - closer surveillance and the importance of co-medication

Updated safety data on JAK inhibitors

Urgency - putting the focus on an important endpoint!

Steroid effects as treatment goals: quality of life and steroid free remission

New endpoints in IBD

Filgotinib is efficacious in inducing and maintaining histological remission in UC

Patient reported outcomes in IBD

Urgency matters!

Neue Studienendpunkte in IBD

Patienten gerichtete Endpunkte bei CED

Explosion of Spanish contributions

Whats's the origin of Crohn's genetics ? The history of IL-23 receptor genetics in Europe

Wo kommt die Crohn-Genetik her? Die Historie der IL-23 Rezeptorgenetik in Europa

Explosión de las comunicaciones españolas

Personalised therapy in IBD

Individualisierte Therapie bei CED